Разработка рабочей аналитической панели биомаркеров дезадаптивного ремоделирования миокарда (систематический обзор)

Автор: Малинова Л.И., Денисова Т.П., Фурман Н.В., Долотовская П.В., Пучиньян Н.Ф., Поварова Т.В.

Журнал: Саратовский научно-медицинский журнал @ssmj

Статья в выпуске: 3 т.15, 2019 года.

Бесплатный доступ

Цель: на основании данных литературы сформировать рабочую аналитическую панель биомаркеров (БМ) дезадаптивного ремоделирования миокарда/дисфункции экстрацеллюлярного матрикса миокарда. Для экстракции данных использовали eLibrary.ru и PubMed. Рассчитывали воспроизводимость полученных данных, интрагрупповые корреляционные связи БМ дезадаптивного ремоделирования миокарда/дисфункции экстра-целлюлярного матрикса миокарда с клиническим фенотипом сердечной недостаточности (СН) - т. Формирование рабочей панели БМ проводилось методом ранжирования (R). В анализ включены данные 5085 публикаций. Наиболее высокая воспроизводимость была у наутрийуретических пептидов ((3 0,91 и 0,89) и сердечных тропонинов ((3 0,84), тогда как наибольшая сила корреляционных отношений БМ и клинического фенотипа СН - у натрийуретических пептидов и ST2 (т 0,81; 0,77 и 0,71). PIIINP и декорин не обнаружили достоверных корреляционных связей с клиническим фенотипом СН. Ранг 0,5 и выше выявлен относительно галектина-3, GDF-15 и остеопонтина. На основании проведенного анализа сформирована совокупность биомаркеров с доказанным участием в патогенезе сердечной недостаточности, которая потенциально обладает наибольшим диагностическим и прогностическим значением, - рабочая аналитическая панель биомаркеров дезадаптивного ремоделирования миокарда/дисфункции экстрацеллюлярного матрикса миокарда: NT-proBNP, BNP, сердечные вч-тропонины, ST2, GDF-15, галектин-3 и остеопонтин.

Еще

Биомаркер, дезадаптивное ремоделирование, натрийуретические пептиды, сердечная недостаточность

Короткий адрес: https://sciup.org/149135388

IDR: 149135388

Список литературы Разработка рабочей аналитической панели биомаркеров дезадаптивного ремоделирования миокарда (систематический обзор)

Wan TTH, Terry A, Cobb E, et al. Strategies to Modify the Risk of Heart Failure Readmission: A Systematic Review and Meta-Analysis. Health services research and managerial epidemiology 2017; 4: 2333392817701050
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016
Gupta A, Allen LA, Bhatt DL, et al. Association of the Hospital Readmissions Reduction Program Implementation with Readmission and Mortality Outcomes in Heart Failure. JAMA cardiology 2017
Maisel A. Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. J Am Coll Cardiol2011;58: 1890-2.
Fonarow GC. Biomarker-Guided vs Guideline-Directed Titration of Medical Therapy for Heart Failure. JAMA 2017; 318: 707-8.
Распространенность ХСН в европейской части Российской Федерации: данные ЭПОХА-ХСН./ И. В. Фомин , Ю. Н. Беленков, В. Ю. Мареев [и др.] // Сердечная недостаточность 2006; 7, 1. 4-7.
Rukosuev VS, Nanaev АК, Samko AN, et al. The localization of the components of the extracellular matrix and cytoskeleton in myocardial biopsies in alcoholic cardiomyopathy Biulleten Vsesoiuznogo kardiologicheskogo nauchnogo tsentra AMN SSSR 1989; 12:88-94.
Sanchez-Quintana D, Garcia-Martinez V, Macias D, Hurle JM. Structural arrangement of the extracellular matrix network during myocardial development in the chick embryo heart. Anatomy and embryology 1991; 184: 451 -60
Frangogiannis NG. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest 2017; 127: 1600-12.
Ueland T, Laugsand LE, Vatten LJ, et al. Extracellular matrix markers and risk of myocardial infarction: The HUNT Study in Norway. Eur J Prev Cardiol 2017; 24: 1161-7.
Emdin M, Vittorini S, Passino C, Clerico A. Old and new biomarkers of heart failure. European Journal of Heart Failure 2009; 11:331-5.
Liu JH, Chen Y, Zhen Z, et al. Relationship of biomarkers of extracellular matrix with myocardial function in Type 2 diabetes mellitus. Biomark Med 2017; 11: 569-78.
Tromp J, Khan MA, Klip IT, et al. Biomarker Profiles in Heart Failure Patients with Preserved and Reduced Ejection Fraction. JAm Heart Assoc 2017; 6
Rockey DC, Bell PD, Hill JA. Fibrosis -A Common Pathway to Organ Injury and Failure. N Engl J Med 2015; 373: 96
Беленков Ю.Н., Привалова E.B., Чекнева И. С. Мозговой натрийуретический пептид - современный биомаркер хронической сердечной недостаточности. Кардиология 2008: 62-9.
Vodovar N, Seronde MF, Laribi S, et al. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J 2014;35:3434-41.
Maisel A. Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. J Am Coll Cardiol 2011; 58: 1890-2.
Sanchez-Mas J, Lax A, Asensio-Lopez MC, et al. Galectin-3 expression in cardiac remodeling after myocardial infarction. Int J Cardiol 2014; 172: e98-e101.
Gonzalez GE, Cassaglia P, Noli Truant S, et al. Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice. Int J Cardiol 2014; 176: 1423-5.
Fiuzat M, Schulte PJ, Felker M, et al. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail 2014; 20: 38-44.
George M, Jena A, Srivatsan V, et al. GDF 15 - A Novel Biomarker in the Offing for Heart Failure. Current cardiology reviews 2016; 12: 37-46.
McLaren JE, Michael DR, Salter RC, et al. IL-33 reduces macrophage foam cell formation. J Immunol 2010; 185: 1222-9.
Willems S, Hoefer I, Pasterkamp G. The role of the Interleukin 1 receptor-like 1 (ST2) and lnterleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment. Minerva Med 2012; 103: 513-24.
Michael DR, Ashlin TG, Davies CS, et al. Differential regulation of macropinocytosis in macrophages by cytokines: implications for foam cell formation and atherosclerosis. cytokine 2013;64:357-61.
Januzzi JL, Jr. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res 2013; 6: 493-500.
Medeiros Nl, Gomes JAS, Correa-Oliveira R. Synergic and antagonistic relationship between MMP-2 and MMP-9 with fibrosis and inflammation in Chagas cardiomyopathy. Parasite Immunol 2017; 39 10.1111 /pirn. 12446
DOI: 10.1111/pirn.12446
Radosinska J, Barancik M, Vrbjar N. Heart failure and role of circulating MMP-2 and MMP-9. Panminerva Med 2017; 59:241-253.
Michalska-Kasiczak M, Bielecka-Dabrowa A, von Haehling S, et al. Biomarkers, myocardial fibrosis and comorbidities in heart failure with preserved ejection fraction: an overview. Archives of medical science (AMS) 2018; 14: 890-909.
Lepojarvi ES, Piira OP, Paakko E, et al. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol 2015; 6: 200
Li G, Yan QB, Wei LM. Serum concentrations of hyaluronic acid, procollagen type III NH2-terminal peptide, and laminin in patients with chronic congestive heart failure. Chin Med Sci J 2006; 21: 175-8.
Medeiros DM, Velleman SG, Jarrold BB, et al. Ontogeny of enhanced decorin levels and distribution within myocardium of failing hearts. Connective tissue research 2002; 43: 32-43.
Chaggar P, Watkins A, Crtichley W, et al. Serum decorin correlates with the heart failure phenotype. Heart Failure Journal 2017; 19 (S. 1): 165
Zhang F, Dang Y, Li Y, et al. Cardiac Contractility Modulation Attenuate Myocardial Fibrosis by Inhibiting TGF- betal/Smad3 Signaling Pathway in a Rabbit Model of Chronic Heart Failure. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 2016; 39: 294-302.
Lopez B, Gonzalez A, Lindner D, et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc Res 2013; 99: 111 -20
Brilla CG. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res 2000; 47: 1-3.
Zhi H, Luptak I, Alreja G, et al. Effects of direct Renin inhibition on myocardial fibrosis and cardiac fibroblast function. PLoSOne2013;8:e81612.
Li C, Han R, Kang L, et al. Pirfenidone controls the feedback loop of the AT1 R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-alpha in myocardial infarction-induced cardiac fibrosis. Sci Rep 2017; 7: 40523
Pavo N, Goliasch G, Wurm R, et al. Low- and High-renin Heart Failure Phenotypes with Clinical Implications. Clin Chem 2017 10.1373/clinchem. 2017.278705.
DOI: 10.1373/clinchem.2017.278705
Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36: 771-8.
Mockel M, Searle J. Copeptin - marker of acute myocardial infarction. Current atherosclerosis reports 2014; 16: 421
Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36: 771-8.
Zhong Y, Wang R, Yan L, et al. Copeptin in heart failure: Review and meta-analysis. Clin Chirm Acta 2017; 475: 36-43.
Liao Y, Takashima S, Maeda N, et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005;67:705-13.
Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10: 1384-9.
Bristow MR, Long CS. Cardiotrophin-1 in heart failure. Circulation 2002; 106: 1430-2.
Lopez B, Gonzalez A, Querejeta R, etal. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 2014; 63: 483-9.
Zile MR, Baicu CF, Ikonomidis JS, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 2015; 131: 1247-59.
Franssen C, Gonzalez Miqueo A. The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2016; 24: 259-67.
Lopez B, Gonzalez A, Ravassa S, et al. Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. J Am Coll Cardiol 2015; 65: 2449-56.
Du W, Piek A, Schouten EM, et al. Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics 2018; 8: 4155-69.

Еще

Статья научная